Synthesis of Nucleic Acid Mimics and Their Application in Nucleic Acid-based Medicine.
Nucleic acid-based drugs (NABDs) have recently attracted considerable attention as next-generation medicines, following the development of low molecular-weight and antibody drugs, because it is likely that they will have fewer side effects and greater target specificity than conventional medicines. Short double-stranded RNAs contain a 2-nucleotide overhang at the 3'-end of each strand. Small interfering RNAs (siRNAs) and microRNAs (miRNAs) inhibit gene expression by RNA interference (RNAi) and thus have great potential as NABDs. However, naked RNA strands have many problems that hinder their application as therapeutics, such as their rapid degradation in biological fluids, poor cellular uptake, and off-target effects. Therefore, artificially modified siRNAs and miRNAs have been studied extensively in an effort to overcome these problems. In this review, I summarize my recent studies on the synthesis of nucleic acid mimics and their application in RNAi-based medicine. The following two topics are specifically discussed: 1) the design and synthesis of chemically modified functional RNAs bearing nucleic acid mimics at their 3'-overhang region, which plays a key role in RNAi; and 2) the practical, reliable synthesis of nucleic acid mimics containing ethynyl groups.
Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University.
Yoshiaki
Y
Kitamura
D000911:Antibodies, Monoclonal; D015195:Drug Design; D015870:Gene Expression; D035683:MicroRNAs; D018716:Molecular Mimicry; D008970:Molecular Weight; D009696:Nucleic Acids / Q000138:chemical synthesis* / Q000737:chemistry; D009711:Nucleotides; D034622:RNA Interference; D012330:RNA, Double-Stranded / Q000737:chemistry; D034741:RNA, Small Interfering
D000911:Antibodies, Monoclonal; D035683:MicroRNAs; D009696:Nucleic Acids; D009711:Nucleotides; D012330:RNA, Double-Stranded; D034741:RNA, Small Interfering